Modality
Degrader
MOA
RAS(ON)i
Target
CDK4/6
Pathway
Sphingolipid
ACCCeliac
Development Pipeline
Preclinical
Jan 2019
→ Mar 2026
PreclinicalCurrent
NCT08235670
1,084 pts·Celiac
2019-01→2026-03·Not yet recruiting
1,084 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-03-011mo agoInterim· Celiac
Trial Timeline
2019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2
Preclinical
Not yet…
Catalysts
Interim
2026-03-01 · 1mo ago
Celiac
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08235670 | Preclinical | Celiac | Not yet recr... | 1084 | SeizFreq |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| MRK-6781 | Merck & Co | Approved | TIGIT | |
| SNY-9073 | Sanofi | Phase 2 | B7-H3 | |
| Motavorutinib | Amgen | Phase 3 | CDK4/6 | |
| Ribozanubrutinib | Regeneron | Phase 1 | CDK4/6 | |
| Tixarelsin | Vertex Pharma | Phase 1 | ALK | |
| MRN-5715 | Moderna | NDA/BLA | CDK4/6 | |
| Fixatuximab | Legend Biotech | Preclinical | CFTR | |
| ION-1378 | Ionis | NDA/BLA | TROP-2 | |
| 180-3597 | Innovent Bio | Preclinical | SHP2 | |
| Elralucimab | Axsome | Phase 2 | CDK4/6 |